Levothyroxine Sodium
NDC 54868-5477
Product Information
Levothyroxine Sodium is a ANDA-approved product labeled by Physicians Total Care, Inc.. Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It is supplied as a gray product. This product entry covers the primary NDC 54868-5477 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
TURQUOISE (C48334)
M;L;10
M;L;15
Code Structure Chart
Product Details
What is NDC 54868-5477?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LEVOTHYROXINE SODIUM (UNII: 9J765S329G)
- LEVOTHYROXINE (UNII: Q51BO43MG4) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BUTYLATED HYDROXYANISOLE (UNII: REK4960K2U)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSPOVIDONE (UNII: 68401960MK)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MANNITOL (UNII: 3OWL53L36A)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POVIDONE (UNII: FZ989GH94E)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- SUCROSE (UNII: C151H8M554)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
- FD&C RED NO. 40 (UNII: WZB9127XOA)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 892251 - levothyroxine sodium 200 MCG Oral Tablet
- RxCUI: 892251 - levothyroxine sodium 0.2 MG Oral Tablet
- RxCUI: 892255 - levothyroxine sodium 300 MCG Oral Tablet
- RxCUI: 892255 - levothyroxine sodium 0.3 MG Oral Tablet
- RxCUI: 966224 - levothyroxine sodium 125 MCG Oral Tablet
* Please review the full disclaimer at the bottom of this page.